Immunogenicity of recombinant HBsAg/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccine

Vaccine

Volumn 21, Issue 21-22, 2003, Pages 2692-2697

  Netter, Hans J ^a,b,c   Woo, Wai Ping ^a,b   Tindle, Robert ^a,b   Macfarlan, Roderick I ^c   Gowans, Eric J ^a,b,d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d BURNET INSTITUTE   (Australia)

Author keywords

Pre existing immune response; Recombinant HBs antigen

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS PARTICLE;

EID: 0038721176     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00182-8     Document Type: Article

References (23)

1. Gedvilaite A., Frömmel C., Sasnauskas K.et al. Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Virology. 273:2000;21-35.
2. Schirmbeck R., Böhm W., Melber K., Reimann J. Processing of exogenous heat-aggregated (denatured) and particulate (native) hepatitis B surface antigen for class I-restricted epitope presentation. J. Immunol. 155:1995;4676-4684.
3. Schirmbeck R., Böhm W., Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Intervirology. 39:1996;111-119.
4. Ganem D, Schneider RJ, Hepadnaviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology, 4th ed., Philadelphia: Williams & Wilkin, Lippincott; 2001, p. 2923-69.
5. Stirk H.J., Thornton J.M., Howard C.R. A topological model for hepatitis B surface antigen. Intervirology. 33:1992;148-158.
6. Delpeyroux F., Chenciner N., Lim A., Lambert M., Malpièce Y., Streeck R.E. Insertions in the hepatitis B surface antigen. J. Mol. Biol. 195:1987;343-350.
7. Delpeyroux F., van Wezel E., Blondel B., Crainic R. Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles. J. Virol. 64:1990;6090-6100.
8. Gordon D.M., McGovern T.W., Krzych U.et al. Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171:1995;1576-1585.
9. Netter H.J., Macnaughton T.B., Woo W.-P., Tindle R., Gowans E.J. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J. Virol. 75:2001;2130-2141.
10. Mazert M.C., Rabier L., Girard M., Goudeau A. Immunogenicity of hepatitis B vaccine in guinea-pigs, mice and man. J. Biol. Stand. 13:1985;221-227.
11. Milich D.R. Immune response to hepatitis B virus proteins: relevance of the murine model. Semin. Liver Dis. 11:1991;93-112.
12. Milich D.R., Chisari F.V. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). H-2 restriction of the murine humoral immune response to the a- and d-determinants of HBsAg. J. Immunol. 129:1982;320-325.
13. Yuasa T., Shimojo H. Potency test of hepatitis B vaccines by the parallel line assay method in mice. Jpn. J. Med. Sci. Biol. 38:1985;9-18.
14. Nakabayashi H., Taketa K., Miyano K., Yamane T., Sato J. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res. 42:1982;3858-3863.
15. Graham F.L., van der Eb A.J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 52:1973;456-467.
16. Barington T., Skettrup M., Juul L., Heilmann C. Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infect. Immun. 61:1993;432-438.
17. Shen X., Lagergård T., Yang Y.et al. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptoccocus type III capsular polysaccharide-cholera toxin B subunit conjugate. Vaccine. 19:2001;3360-3368.
18. Ben-Yedidia T., Arnon R. Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Immunol. Lett. 64:1998;9-15.
19. Etlinger H.M., Gillessen D., Lahm H.W., Matile H., Schonfeld H.J., Trzeciak A. Use of prior vaccinations for the development of new vaccines. Science. 249:1990;423-425.
20. Lycke N., Schön K. The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity. Vaccine. 19:2001;2542-2548.
21. Schutze M.P., Deriaud E., Przewlocki G., LeClerc C. Carrier-induced epitopic suppression is initiated through clonal dominance. J. Immunol. 142:1989;2635-2640.
22. Shah S., Raghupathy R., Singh O., Talwar G.P., Sodhi A. Prior immunity to a carrier enhances antibody responses to hCG in recipients of an hCG-carrier conjugate vaccine. Vaccine. 17:1999;3116-3123.
23. World Health Organization. Hepatitis B. Fact Sheet WHO 2000;204: Revised October 2000.